ZyVersa Therapeutics, Inc. Annual Income Tax Expense (Benefit) in USD for 2023

Taxonomy & unit: us-gaap: USD
Description: Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
Summary: ZyVersa Therapeutics, Inc. quarterly/annual Income Tax Expense (Benefit) history and growth rate for 2023.
ZyVersa Therapeutics, Inc. Income Tax Expense (Benefit) for the quarter ending June 30, 2024 was $9.71K.

Income Tax Expense (Benefit), Trailing 12 Months (USD)

Income Tax Expense (Benefit), Annual (USD)

Period	Value	YoY Chg	Change %	Start Date	End Date	Report	Filed
2023	-$9.46M			Jan 1, 2023	Dec 31, 2023	10-K	2024-03-25

* An asterisk sign (*) next to the value indicates that the value is likely invalid.